Immunovant, Inc.
US ˙ NasdaqGS ˙ US45258J1025

SecurityIMVT / Immunovant, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership3,876,877 shares
Latest Disclosed Value $ 96,301,649
Morgan Stanley reports 20.00% decrease in ownership of IMVT / Immunovant, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 3,876,877 shares of Immunovant, Inc. (US:IMVT) valued at $96,301,625 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 4,846,385 shares of Immunovant, Inc.. This represents a change in shares of -20.00% during the quarter. The current value of the position is $126,657,572 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F IMMUNOVANT COM 45258J102 3,876,877 -969,508 -20.00 96,302 -21.83 0.0058
2026-05-27 2025-12-31 13F/A-1 IMMUNOVANT COM 45258J102 4,846,385 2,887,359 147.39 123,195 290.12 0.0074
2026-02-13 2025-12-31 13F IMMUNOVANT COM 45258J102 4,846,385 2,887,359 123,195 0.0074
2026-05-27 2025-09-30 13F/A-1 IMMUNOVANT COM 45258J102 1,959,026 -350,035 -15.16 31,580 -14.52 0.0019
2025-11-14 2025-09-30 13F IMMUNOVANT COM 45258J102 1,959,026 -350,035 31,580 0.0019
2025-08-15 2025-06-30 13F IMMUNOVANT COM 45258J102 2,309,061 999,011 76.26 36,945 65.02 0.0024
2025-05-15 2025-03-31 13F IMMUNOVANT COM 45258J102 1,310,050 299,426 29.63 22,389 -10.57 0.0016
2025-05-15 2024-12-31 13F/A-1 IMMUNOVANT COM 45258J102 1,010,624 192,882 23.59 25,033 7.38 0.0018
2025-02-14 2024-12-31 13F IMMUNOVANT COM 45258J102 1,010,624 192,882 25,033 0.0018
2025-05-14 2024-09-30 13F/A-2 IMMUNOVANT COM 45258J102 817,742 704 0.09 23,314 8.09 0.0017
2025-02-14 2024-09-30 13F/A-1 IMMUNOVANT COM 45258J102 817,742 704 23,314 0.0017
2024-11-14 2024-09-30 13F IMMUNOVANT COM 45258J102 817,742 704 23,314 0.0002
2025-05-14 2024-06-30 13F/A-2 IMMUNOVANT COM 45258J102 817,038 -120,923 -12.89 21,570 -28.83 0.0017
2024-10-17 2024-06-30 13F/A-1 IMMUNOVANT COM 45258J102 817,038 -120,923 21,570 0.0017
2024-08-14 2024-06-30 13F IMMUNOVANT COM 45258J102 817,038 -120,923 21,570 0.0017
2024-10-17 2024-03-31 13F/A-2 IMMUNOVANT COM 45258J102 937,961 406,458 76.47 30,306 35.34 0.0024
2024-08-16 2024-03-31 13F/A-1 IMMUNOVANT COM 45258J102 937,961 406,458 30,306 0.0003
2024-05-15 2024-03-31 13F IMMUNOVANT COM 45258J102 937,961 406,458 30,306 0.0024
2024-08-16 2023-12-31 13F/A-1 IMMUNOVANT COM 45258J102 531,503 192,620 56.84 22,392 72.13 0.0020
2024-02-13 2023-12-31 13F IMMUNOVANT COM 45258J102 531,503 192,620 22,392 0.0020
2023-11-15 2023-09-30 13F IMMUNOVANT COM 45258J102 338,883 -198,173 -36.90 13,010 27.70 0.0013
2023-08-14 2023-06-30 13F IMMUNOVANT COM 45258J102 537,056 309,965 136.49 10,188 189.24 0.0010
2023-05-15 2023-03-31 13F IMMUNOVANT COM 45258J102 227,091 56,841 33.39 3,522 16.58 0.0004
2023-02-14 2022-12-31 13F IMMUNOVANT COM 45258J102 170,250 77,819 84.19 3,022 485.47 0.0003
2022-11-14 2022-09-30 13F IMMUNOVANT COM 45258J102 92,431 -67,240 -42.11 516 -17.04 0.0001
2022-10-27 2022-06-30 13F/A-1 IMMUNOVANT COM 45258J102 159,671 -68,351 -29.98 622 -50.48 0.0001
2022-08-15 2022-06-30 13F IMMUNOVANT COM 45258J102 159,671 -68,351 622 0.0000
2022-10-27 2022-03-31 13F/A-1 IMMUNOVANT COM 45258J102 228,022 -268,888 -54.11 1,256 -70.34 0.0002
2022-05-13 2022-03-31 13F IMMUNOVANT COM 45258J102 228,022 -268,888 1,256 0.0002
2022-02-14 2021-12-31 13F IMMUNOVANT COM 45258J102 496,910 -368,336 -42.57 4,234 -43.69 0.0005
2021-11-15 2021-09-30 13F IMMUNOVANT COM 45258J102 865,246 -677,126 -43.90 7,519 -53.88 0.0010
2021-08-23 2021-06-30 13F/A-1 IMMUNOVANT COM 45258J102 1,542,372 789,721 104.93 16,303 35.05 0.0022
2021-08-16 2021-06-30 13F IMMUNOVANT COM 45258J102 1,542,372 789,721 16,303 0.0004
2021-05-17 2021-03-31 13F IMMUNOVANT COM 45258J102 752,651 675,882 880.41 12,072 240.44 0.0018
2021-02-16 2020-12-31 13F IMMUNOVANT COM 45258J102 76,769 71,395 1,328.53 3,546 1,766.32 0.0005
2020-11-13 2020-09-30 13F IMMUNOVANT COM 45258J102 5,374 -1,569 -22.60 190 12.43 0.0000
2020-08-14 2020-06-30 13F IMMUNOVANT COM 45258J102 6,943 -13,233 -65.59 169 -46.18 0.0000
2020-05-26 2020-03-31 13F/A-1 IMMUNOVANT COM 45258J102 20,176 19,176 1,917.60 314 1,862.50 0.0001
2020-05-15 2020-03-31 13F IMMUNOVANT COM 45258J102 20,176 19,176 314 24.1217
2020-02-14 2019-12-31 13F IMMUNOVANT COM 45258J102 1,000 1,000 16 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.